Education
About Us
Working with TipRanks
Follow Us
Allogene Therapeutics Inc (ALLO)
NASDAQ:ALLO
RESEARCH TOOLSreports
ALLO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.32 - $5.78
Previous CloseN/A
Volume1.66M
Average Volume (3M)7.61M
Market Cap
$408.86M
Enterprise Value$386.69M
Total Cash (Recent Filing)$83.16M
Total Debt (Recent Filing)$95.12M
Price to Earnings (P/E)―
Beta2.17
Next Earnings
Apr 30, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding209,672,090
10 Day Avg. Volume17,779,273
30 Day Avg. Volume7,606,646
Standard Deviation0.21
R-Squared0.04
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4303.80
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market Cap0.95
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.59
Enterprise Value/Ebitda-1.49
Forecast
1Y Price Target
$11.50Price Target Upside489.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Allogene Therapeutics News
---
Bulls Say, Bears Say
Bulls Say
Efficacy DataUpdated Phase I ALPHA/ALPHA 2 Data Supports Efficacy Profile of Cema-Cel.
Product InnovationAllogene's ALLO-329 avoids halting immunosuppression for several weeks before T-cell apheresis, because ALLO-329 is a ready-to-use product.
Bears Say
Program DiscontinuationThe discontinuation of the CLL program is seen as unfortunate due to slower-than-anticipated trial enrollment and the emergence of new alternative treatment options.
---
Ownership Overview
10.22% Insiders
25.78% Mutual Funds
<0.01% Other Institutional Investors
53.13% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALLO FAQ
What was Allogene Therapeutics Inc’s price range in the past 12 months?
Allogene Therapeutics Inc lowest stock price was $1.32 and its highest was $5.78 in the past 12 months.
What is Allogene Therapeutics Inc’s market cap?
Allogene Therapeutics Inc’s market cap is $408.86M.
When is Allogene Therapeutics Inc’s upcoming earnings report date?
Allogene Therapeutics Inc’s upcoming earnings report date is Apr 30, 2025 which is in 58 days.
How were Allogene Therapeutics Inc’s earnings last quarter?
Currently, no data Available
Is Allogene Therapeutics Inc overvalued?
According to Wall Street analysts Allogene Therapeutics Inc’s price is currently Undervalued.
Does Allogene Therapeutics Inc pay dividends?
Allogene Therapeutics Inc does not currently pay dividends.
What is Allogene Therapeutics Inc’s EPS estimate?
Allogene Therapeutics Inc’s EPS estimate is -0.33.
How many shares outstanding does Allogene Therapeutics Inc have?
Allogene Therapeutics Inc has 209,672,090 shares outstanding.
What happened to Allogene Therapeutics Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Allogene Therapeutics Inc?
Currently, no hedge funds are holding shares in ALLO
---
Allogene Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.50 (489.74% Upside)
$11.50 (489.74% Upside)
Blogger Sentiment
Bullish
ALLO Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $39.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.91%
12-Months-Change
Fundamentals
Return on Equity
-54.15%
Trailing 12-Months
Asset Growth
-17.30%
Trailing 12-Months
Company Description
Allogene Therapeutics Inc
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
---
ALLO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in clinical trials for both cancer and autoimmune diseases, showing promising efficacy and strong financial positioning. However, concerns about safety profiles and delays in regimen finalization pose challenges.Read More>---
ALLO Stock 12 Month Forecast
Average Price Target
$11.50
▲(489.74% Upside)
Technical Analysis
Bluebird Bio
―
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering ALLO
1 Year
1 Year Success Rate
5/20 ratings generated profit
1 Year Average Return
-23.91%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -23.91% per trade.
---